What question did this study set out to answer?

To estimate the global, regional, and national prevalence of hepatitis B virus, related mortality, and disability-adjusted life-years between 1990 and 2019, and evaluate progress toward WHO elimination targets across 194 countries.

June 20, 2022The Lancet. Gastroenterology & hepatologyOpen Access

Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

View Full Paper

Ask AI

Bookmark

Authors

BSBrittney S SheenaInstitute for Health Metrics and Evaluation LHLindsey HiebertNorthern Arizona University HHHannah HanHoag Memorial Hospital Presbyterian

Discussion

Member takes

Implication

Systematic analysis reveals a global decline in hepatitis B prevalence alongside rising total deaths in 194 countries, highlighting the urgent need to scale up testing and vaccination.

Key Points

To estimate the global, regional, and national prevalence of hepatitis B virus, related mortality, and disability-adjusted life-years between 1990 and 2019, and evaluate progress toward WHO elimination targets across 194 countries.
Extracted data from population-based serosurveys, vital registration systems, cancer registries, hospital discharge databases, and published case series across 194 WHO member states.
Used DisMod-MR 2.1 Bayesian meta-regression to estimate chronic HBV infection and cirrhosis prevalence, and Cause of Death Ensemble modelling (CODEm) to assess mortality from acute hepatitis B, cirrhosis, and liver cancer.
In 2019, global all-age chronic HBV prevalence was 4.1% (95% UI 3.7 to 4.5), representing 316 million infected people and a 31.3% (95% UI 29.0 to 33.9) decline since 1990, with a 76.8% (95% UI 76.2 to 77.5) decline in children younger than 5 years.
HBV-related diseases caused 555,000 global deaths (95% UI 487,000 to 630,000) in 2019, representing a 5.9% (95% UI -5.6 to 19.2) increase in total deaths since 1990 despite falling age-standardized mortality rates.
By 2019, 147 of 194 countries met the WHO target of <1% prevalence in children younger than 5 years, but only four achieved the 10% mortality reduction target and 15 met the 30% incidence reduction target.

Cite This Study

Sheena et al. (2022) studied this question.

synapsesocial.com/papers/6a7fe842eaf37ab6fb502cd8 https://doi.org/10.1016/s2468-1253(22)00124-8

View Full Paper

Ask AI

Bookmark

Implication

Systematic analysis reveals a global decline in hepatitis B prevalence alongside rising total deaths in 194 countries, highlighting the urgent need to scale up testing and vaccination.

Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Discussion

Member takes

Implication

Key Points

Cite This Study

Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider